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ABSTRACT An organism requires a range of biomolecules for its growth. By definition, these are essential molecules which consti-
tute the basic metabolic requirements of an organism. A small organic molecule with chemical similarity to that of an essential
metabolite may bind to the enzyme that catalyzes its production and inhibit it, likely resulting in the stasis or death of the organ-
ism. Here, we report a high-throughput approach for identifying essential metabolites of an organism using genetic and bio-
chemical approaches and then implement computational approaches to identify metabolite mimics. We generated and geno-
typed 5,126Mycobacterium tuberculosismutants and performed a statistical analysis to determine putative essential genes. The
essential molecules ofM. tuberculosiswere classified as products of enzymes that are encoded by genes in this list. Although in-
complete, as many enzymes ofM. tuberculosis have yet to be identified and characterized, this is the first report of a large num-
ber of essential molecules of the organism.We identified essential metabolites of three distinct metabolic pathways inM. tuber-
culosis and selected molecules with chemical similarity using cheminformatics strategies that illustrate a variety of different
pharmacophores. Our approach is aimed at systematic identification of essential molecules and their mimics as a blueprint for
development of effective chemical probes ofM. tuberculosismetabolism, with the ultimate goal of seeking drugs that can kill this
pathogen. As an illustration of this approach, we report that compounds JFD01307SC and L-methionine-S-sulfoximine, which
share chemical similarity with an essential molecule ofM. tuberculosis, inhibited the growth of this organism at micromolar
concentrations.
IMPORTANCE The estimate that more lives may have been lost in 2009 due to tuberculosis (TB) than in any year in history is
alarming. Approximately 9.2 million new cases and 1.8 million deaths due to TB were reported in 2008. The widespread preva-
lence ofMycobacterium tuberculosis strains that are resistant to drugs currently used to treat TBmeans that new drugs are ur-
gently needed to treat these infections. Here, we have identified pathways for the biosynthesis of essential metabolites and associ-
ated enzymes inM. tuberculosis using a genetics-based approach. Small molecules that mimic these essential metabolites were
identified, and some of them were shown to inhibit the growth ofM. tuberculosis. Therefore, we illustrate an approach based on
genetics to develop inhibitors that have the potential to be advanced as candidate drugs for treating TB.
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The availability of whole-genome sequences of bacterial patho-gens was rapidly followed by high-throughput identification
of genes essential for their proliferation. One of the main goals of
these studies was to identify proteins that could be targeted for
inhibition of growth, with the ultimate aim of developing drugs to
treat infections with the pathogens.Mycobacterium tuberculosis is
the etiological agent of tuberculosis (TB), an infectious disease of
which ~9 million new cases and ~1.7 million mortalities were
reported for the year 2009 (1). Seminal studies of the global bur-
den of TB conducted by theWHOhave declared drug-susceptible
M. tuberculosis or readily treatable TB a global health emergency
(2, 3). New and effective drugs are required, as existing drugs have
become suboptimal in many settings due to the requirement for
protracted periods of treatment and the emergence of multiple-
and extensively drug resistant strains of M. tuberculosis (4, 5).
Identification of genes that encode essential proteins is a first step
toward determining targets whose inhibition may result in the
arrest of growth or killing ofM. tuberculosis.
In a seminal study, Sassetti and colleagues used a high-
throughput method based on a whole-genome microarray to
identify essential genes ofM. tuberculosis by randommutagenesis
(6). This essential gene set of M. tuberculosis represents the basic
requirement for the growth and proliferation of the organism in a
defined medium in vitro. The availability of these data facilitated
further investigations to map the metabolic pathways and metab-
olites required by M. tuberculosis for proliferation. Given our fo-
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cus on the development of drugs against TB based on targeting the
essential metabolic machinery of M. tuberculosis, we herein pro-
vide a proof of concept for how onemay transition from an essen-
tial gene to an enzyme to an essential metabolite to a potential
inhibitor of the enzyme with whole-cell viability.
M. tuberculosis, like any organism, requires an array of biomol-
ecules for its survival. These biomolecules either are obtained
from the environment or are synthesized de novo. An enzyme that
catalyzes the biosynthesis of an essential metabolite is itself essen-
tial, if we assume that there are no alternative enzymes or meta-
bolic pathways capable of synthesizing the same metabolite.
Therefore, inhibiting essential enzymes is an effectiveway to kill or
arrest the growth of an organism.
Many drugs that are highly successful in human clinical use
mimic a substrate or a product of essential enzymes. For example,
folic acid is an essential biomoleculewhich needs to be synthesized
de novo by many bacteria, and dihydropteroate synthase, an en-
zyme in the folic acid biosynthesis pathway, synthesizes dihydro-
folate from p-aminobenzoate (7). Sulfonamide-based drugs are
structural analogs of p-aminobenzoate and act by inhibiting dihy-
dropteroate synthase (8). Many bacterial infections are effectively
treated with sulfonamides, as they mimic an essential substrate
and competitively inhibit an essential enzyme. Another well-
known class of drugs that mimics an essential biomolecule is the
-lactam group of antibiotics (9). They possess a core four-
membered ring thatmimics the structure of the terminal D-alanyl-
D-alanine subunit of the peptidoglycan layer in bacterial cell walls.
This peptidoglycan layer is essential for the survival of bacteria, as
it is required for maintenance of cell structure (10). Transpepti-
dases required for cross-linking of peptide chains to network the
peptidoglycan layer use terminal D-alanyl-D-alanine as a substrate.
By mimicking the natural substrate, -lactams engage the
transpeptidases and inhibit their actions, leading to destruction of
the peptidoglycan layer and the eventual death of the organism
(11). There are numerous other examples of inhibition of essential
enzymes by mimicking their substrates.
In this study, we identified essential metabolites ofM. tubercu-
losis using the strategy summarized in Fig. 1. We began by identi-
fying genes and associated enzymes that are essential for the
growth and proliferation of the bacterium. For this we used the
Himar1 transposon to disrupt genes ofM. tuberculosis. Nearly all
genes are susceptible to disruption, as the transposon requires
only the TA dinucleotide for insertion (12). The transposon is
delivered into M. tuberculosis cells using suicide mycobacterio-
phage, and the transduced mutants are obtained from drug-
containing plates (13, 14). A genome walking technique was used
to locate the site of transposon insertion and to determine the
identity of the disrupted gene (15). Genes whose disruptions do
not compromise the growth of the bacilli are classified as nones-
sential.
Our method is based on sequencing of the site of mutagenesis
to identify nonessential genes and, subsequently, the essential
genes (15). We then identify metabolites that are essential for the
growth and proliferation ofM. tuberculosis as the products of re-
actions catalyzed by enzymes encoded by essential genes. Our cur-
rent collection contains 5,126 independent, genotyped, and ar-
chived mutants with disruptions in both intra- and intergenic
regions. A statistical analysis was performed to predict the essen-
tiality of the genes that we were unable to disrupt. Here, we report
that the pathways for peptidoglycan, tetrapyrrole, and chorismate
biosynthesis are essential for the growth of M. tuberculosis. The
products of the enzymes that comprise these pathways are identi-
fied as essential metabolites. We then discuss a cheminformatics
strategy to identify mimics of the essentialM. tuberculosismetab-
olites that may be rational competitive inhibitors of the essential
enzymes and may thereby kill or inhibit the growth of M. tuber-
culosis. These mimics are starting points for further development
of molecules with increased-potency activity against M. tubercu-
losis for use as chemical probes of metabolism or as antitubercular
agents.
RESULTS
Identification of nonessential and essential genes.We created a
library of 5,126 unique transposon insertionmutants ofM. tuber-
culosis. This collection represents the disruption and therefore loss
of function of 2,246 unique genes. As wewere able to isolate viable
mutants, we define the genes disrupted in these mutants to be
nonessential for in vitro growth. In order to ensure that the func-
tion of any gene classified as nonessential was truly disrupted by
mutagenesis, all genes with far-distal insertions, as defined by the
5= 80%/3= 100-bp test (which qualifies a transposon insertion in
the proximal [5=] 80% of the gene or upstream of the distal [3=]
100 bp of the gene to be able to effectively disrupt the gene), were
excluded from the nonessential gene list (15). Two hundred
twelve genes were found with distal insertions and removed from
the nonessential gene list (see Table S1 in the supplemental mate-
rial). Similarly, if a disrupted gene had an isoenzyme that catalyzed
the same reaction, the function of the disrupted genewould not be
affected since the isoenzyme would carry out the reaction in the
mutant. In these cases, the identification of a mutant with a single
insertion in a gene with an isoenzyme was irrelevant to whether
that gene’s function is essential for in vitro growth. Twenty-four
FIG 1 Schematic for identification of essential molecules and their mimics.
The genome of an organism is mutagenized to saturation, and nonessential
genes whose loss does not compromise the ability of an organism to proliferate
are identified. The genes whose loss could not be tolerated are essential and
code for essential proteins that have structural or regulatory functions or are
enzymes. The metabolite(s) that is produced by an essential enzyme is deter-
mined, and its molecular mimic(s) with pharmacological potential is identi-
fied using cheminformatics. These mimics may bind to the essential enzyme,
inhibit its function, and eventually kill the organism.
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disrupted geneswere found to have isoenzymes andwere removed
from the nonessential list. Finally, genes that were not disrupted
were reclassified as nonessential if they belonged to an operon
with an insertion proximal to the gene of interest due to a likely
polar effect on such genes. A total of 534 nondisrupted genes were
classified as nonessential because their operons contained a prox-
imal insertion. This filtering process thus left us with essential
genes under this specific in vitro growth condition.
The metabolic requirement and avail-
ability of nutrients during an infection
differ from the in vitro conditions that
were used to identify essential genes in
our study. Certain metabolites that have
to be synthesized de novo during growth
in vitro may be available in macrophages
or in the extracellular environment dur-
ing an infection, allowing the organism to
bypass the requirement to synthesize the
metabolites that may be identified as es-
sential in our study and vice versa. There-
fore, our method clearly does not identify
all the metabolites required for growth
and proliferation during an infection.
However, as our understanding grows
with respect to how the metabolism ofM.
tuberculosis changes given its environ-
ment, we anticipate application of our
methodology to derive state-specific es-
sential genes.
Definition of the essential molecules
of M. tuberculosis and exemplary path-
ways. Approximately 40% ofM. tubercu-
losis genes are annotated as “hypotheti-
cal,” as they encode proteins whose
functions have yet to be characterized
(16). In this study, we focused on the
genes that encode enzymes with homol-
ogy to known enzymes, allowing facile
identification of their products, which we
hereby define as essential metabolites. At
this time, we count 401 essential enzyme-
encoding genes of M. tuberculosis via our
genetic method, which should afford as
many nonredundant essential metabo-
lites of M. tuberculosis. Rather than ex-
haustively enumerate each of these, we
have instead chosen to discuss three path-
ways where each of the steps processes an
essential metabolite, thus highlighting the
critical role they play in M. tuberculosis
metabolism. Essential metabolites of
these pathways, namely, peptidoglycan,
chorismate, and tetrapyrrole biosynthe-
sis, their potential molecular mimics, and
their respective chemical similarities and
known pharmacological information are
presented (see Table S2 in the supplemen-
tal material).
The peptidoglycan biosynthetic path-
way begins with an assembly of sugar and
amino acid residues to generate a disaccharyl-pentapeptide (or
tetrapeptide). The associated reactions occur internal to the
plasma membrane and are catalyzed by a series of enzymes. This
pathway and associated putative enzymes are shown in Fig. 2A.
The core of the pathway begins with conversion ofUDP-N-acetyl-
D-glucosamine to UDP-N-acetyl-D-glucosamine-enol pyruvate
and ends with generation of disaccharyl-pentapeptide, GlcNAc-
MurNAc-L-Ala1-D-iGln2-mesoDapNH23-D-Ala4-D-Ala5 (17). Fig-
FIG 2 (A) Genes andmetabolites that comprise the pathway for the biosynthesis of the building blocks
of peptidoglycan in M. tuberculosis; (B) composite of 23 genes of M. tuberculosis of the peptidoglycan
biosynthesis pathway (right) and a depiction of random loci with identical sizes and TA densities. The
arrows show the number of transposon insertions that each locus was able to sustain.
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ure 2A also lists putative genes that encode enzymes associated
with de novo biosynthesis of amino acid residues that comprise the
pentapeptide chain. These 23 genes that constitute the peptidogly-
can biosynthesis pathway contain a total of 416 eligible TA trans-
position sites that may be disrupted by the transposon. However,
none of these sites could sustain a viable insertion disruption, as
they were not represented among the 5,126 independent mutants
in our collection. Figure 2B depicts a composite locus for all genes
that comprise the peptidoglycan biosynthesis pathway and an-
other random locus that is identical in size and TA density. Ac-
cording to our mutagenesis data, the random locus sustained 36
transposition disruptions, whereas none were observed in the loci
for the peptidoglycan biosynthesis pathway.We used these data to
assess the essentiality of the pathway given that there are 63,956
total TA sites in the open reading frames of the M. tuberculosis
genome. The P value for the likelihood that the pathway for pep-
tidoglycan biosynthesis is essential is 3.52 1015. Therefore, we
conclude that the pathway for peptidoglycan biosynthesis is essen-
tial for the growth and survival of M. tuberculosis. Disruption of
the above-mentioned genes that constitute the peptidoglycan bio-
synthesis pathway was also not observed in a comprehensive mu-
tagenesis study undertaken by Sassetti et al. (6). The constituent
essential metabolites of this pathway are shown in Table 1.
The chorismate pathway is common to the biosynthesis of
L-tryptophan, L-tyrosine, and folic acid and consists of seven
genes, aroA to -C, -E, -G, -K, and -Q inM. tuberculosis. The aroC,
-K, -B, and -Q genes are located in a putative operon, while aroA,
-E, and -G are scattered around the genome. Each of these genes
has multiple TA sites and is thus susceptible to insertion disrup-
tion by Himar1 transposon. However, we were unable to isolate
viable mutants with disruption of any of these genes despite our
attempts, resulting in 5,126 unique mutants. Our statistical anal-
ysis for the probability of this observation yielded a P value of
0.007. Therefore, we conclude that the pathway for chorismate
biosynthesis is essential for the survival and growth ofM. tubercu-
losis, and its essential molecules are shown in Table 2. It should be
noted that a previous study showed that M. tuberculosis aroK is
essential, as the investigators were unable to isolate a mutant with
a deletion of this gene (18).
M. tuberculosis possesses six conserved genes that are dedicated
to tetrapyrrole biosynthesis. The genes hemA to -D, hemL, and gltS
are located in three regions in the chromosome. The hemA to -D
genes comprise a putative operon. The loci containing hemABCD,
adjacent genes, and the sites at which the Himar1 transposon has
inserted are shown (see Fig. S1 in the supplemental material).
None of the genes that comprise the tetrapyrrole biosynthesis
pathway have sustained a transposon insertion. The P value for
not observing a transposon insertion in any of the genes in our
collection of 5,126 genotyped mutations is 7  105. Therefore,
we conclude with high confidence that the pathway for tetrapyr-
role biosynthesis is essential inM. tuberculosis. The essential mol-
ecules of this pathway are listed elsewhere (see Table S3 in the
supplemental material).
Search for mimics of essential metabolites using cheminfor-
matics strategies.The essentialmetabolites ofM. tuberculosis rep-
resent a significant resource in the search for chemical probes/
tools of metabolism that may inspire novel antitubercular
therapeutics. While the specific biological activity of an essential
molecule is critical to these applications, in most cases, one ex-
pects a lack of drug-like properties to limit utility. A number of
strategies can be considered for identifying a set ofmore druggable
small molecules that mimic an essential molecule. Principally, all
strategies should involve utilization of the neighborhoodprinciple
(19, 20), which states that structurally similar molecules should
exhibit similar properties and, in particular, biological activities.
This approach has been used frequently in drug discovery (21–24)
and in other areas, such as therapeutic drugmonitoring (25). Dif-
ferent computational metrics may be used to assess the similarity
of twomolecules, including one-dimensional (1-D), 2-D, and 3-D
methods (24, 26). Quite simply, for example, one can use Tani-
moto similarity (24) to find 2-D similarmoleculesmeeting a given
level of similarity (the higher the better) to the identified essential
metabolite. Another approach is to generate a 3-D pharmacoph-
ore around a molecule (27), perhaps with some molecular shape
TABLE 1 Representative essential molecules of the peptidoglycan biosynthesis pathway in M. tuberculosis and their mimics
Essential molecule
Molecule ID, % similarity, MIC90 forM. tuberculosis (g/ml),
and structure of an analoga
UDP-GlcNAc-enol pyruvate 48239, 52, 0.237 351369, 57, 0.13
meso-Diaminopimelate 92585, 52, 0.21 341652, 62, 43
D-Alanyl-D-alanine 58257, 51 344159, 53, 29.5
a Representative essential molecules of the pathway for peptidoglycan biosynthesis inM. tuberculosis and examples of existing analogs. An identification provided by the CDD
database (molecule ID), percent similarity to the corresponding essential molecule, and MIC90 forM. tuberculosis are shown. The MIC90 data are compiled in the CDD database
from various laboratories. The percent inhibition of molecule 58257 at a 10 M concentration was 8.98%.
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restriction to form a 3-D query, which could be used to search
large multiconformer libraries of compounds. Examples of such
compound libraries to be searched could include molecules with
antitubercular activity, at the whole-cell and/or enzyme or target
level, such as those available in the Collaborative Drug Discovery
(CDD) TB database, consisting of many individual data sets of
compounds tested against TB, malaria, and other diseases (27,
28). Searching metabolite databases, such as the Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) (29, 30) and LipidMaps
(31), or databases composed of commercially available molecules
like those found in ChemSpider (32), eMolecules, and ZINC (33)
could also be fruitful for identifying similar molecules for poten-
tial testing.
We have chosen for our first attempts in essential molecule
mimicry to rely on 2-D Tanimoto similarity. The choice of Tani-
moto similarity rests not only on its relative simplicity but also on
our previously reported finding that azaserine potently inhibitsM.
tuberculosis glutamate synthase (GltB) (15). GltB is an essential
enzyme which catalyzes the formation of L-glutamate from
L-glutamine and 2-ketoglutarate. An analysis of the 2-D similarity
of L-glutamate and azaserine using the ChemAxon hashed-
fingerprint methodology in the CDD TB database yields a Tani-
moto value of 33%.We hypothesized that azaserinemay bind and
inhibit glutamate synthase by mimicking the natural substrate of
this enzyme. In order to test this hypothesis, we created an M.
tuberculosis strain overexpressing gltB and determined theMIC of
azaserine using the broth dilution method (34). Quantitative re-
verse transcription-PCR (RT-PCR) revealed a 3.2-fold increase in
the expression of gltB in the recombinant strain overexpressing
this gene. The MICs for wild-type M. tuberculosis CDC1551 and
the strain overexpressing gltB were 0.25 to 0.5 g/ml and 1.0 to
2.0 g/ml, respectively. As a control, we also determined the MIC
of isoniazid, as GltB is not known to be the target for this drug;
wild-type M. tuberculosis CDC1551 and gltB-overexpressing
strains exhibited identical susceptibilities (MICs of 0.03 to
0.06 g/ml). While overexpression mutants may be subject to
higher-order metabolic perturbations due to feedback or com-
pensations in connected pathways, we assert that the 4-fold in-
crease in MIC due to increased expression of gltB is supportive of
the idea that azaserine, a mimic of the natural substrate of GltB,
inhibits this enzyme.
Examining a more sophisticated and tunable informatics
strategy, we turned to 3-D pharmacophore searching. Specifi-
cally, we generated a common-feature pharmacophore model
for L-glutamate in Discovery Studio 2.5.5. The pharmacophore
consisted of a positive ionizable feature for the -amino group,
a negative ionizable feature for the -carboxyl moiety, and a
hydrogen bond acceptor feature for the side chain carboxylate
TABLE 2 Essential molecules of the chorismate biosynthesis pathway in M. tuberculosis and their mimics
Essential molecule Molecule ID, % similarity, MIC90 forM. tuberculosis (g/ml), and structure of an analoga
3-Dehydroquinate 17699, 55, 14.7 52283. 56, 2.07 110597, 70, 7.1
3-Dehydro-shikimate 209508, 50, 12.0 398410, 52, 2.3 398407, 52, 4.6
Shikimate-3-phosphate 50320, 41, 73 170440, 42, 14.4 340891, 43, 10
5-Enolpyruvyl-shikimate-3-phosphate 340430, 52, 3.1 163046, 55 168409, 56
Chorismate 167369, 45. 0.98 340733, 50, 26 53251, 50, 10.16
a Representative essential molecules of the pathway for chorismate biosynthesis inM. tuberculosis and examples of existing analogs. An identification provided by the CDD
database, percent similarity to the corresponding essential molecule, and MIC90 forM. tuberculosis are shown. The MIC90 data are compiled in the CDD database from various
laboratories. The percent inhibition of molecule 163046 at a 10 M concentration was 8.8%, and that for molecule 168409 was 48.6%.
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(see Fig. S2 in the supplemental material). The constraint
around the side chain carboxylate was “relaxed” from a nega-
tive ionizable feature to a hydrogen bond acceptor feature in
order to avoid returning diacids as hits, which in our experi-
ence fail to exhibit whole-cell activity due to the lack of M.
tuberculosis permeability. Azaserine, in addition to exhibiting
Tanimoto similarity to L-glutamate, favorably fits this pharma-
cophore model, possessing chemical moieties mapping to all
three pharmacophoric elements and a FitValue (reflecting
goodness of fit to the model) of 2.1. This 3-D model was uti-
lized to search conformer databases of commercial compounds
chosen from Asinex, Maybridge, and Microsource. The phar-
macophore model was selective, because, for example, only 130
out of 2,642 FDA-approved drugs and 199 out of 57,181 May-
bridge compounds fit and were scored with a FitValue. Visual
inspection of hits afforded 12 molecules for purchase that were
assayed (Table 3 and see Table S4 in the supplemental material).
As a collection, all of these putative mimics maintain the
-carboxyl group in close spatial proximity to a basic amine, while
displaying a variety of polar functionalities with hydrogen bond-
accepting ability. Among these compounds, JFD01307SC and
L-methionine-S-sulfoximine showed activity against M. tubercu-
losis, with MICs in the range of 8 to 16 g/ml and 8 to 12 g/ml,
respectively. To our surprise, we observed the susceptibility of the
M. tuberculosis strain overexpressing gltB to the two compounds
to be similar to that of the wild-type strain. We hypothesize that
the observed activity of JFD01307SC and L-methionine-S-
sulfoximinemay have resulted from a target that is similar toGltB,
or the compounds are metabolized into more than one active
molecule. L-Methionine-S-sulfoximine is known to inhibit glu-
tamine synthase in humans and M. tuberculosis (35). Given the
structural similarity of glutamine and glutamate and their shared
TABLE 3 Examples of biomolecules that are essential for the metabolism and survival ofM. tuberculosis and their structural analogsa
Essential molecule and structure Structural analog
%
similarity
Activity against
M. tuberculosis
Reference
or source
L-Glutamate Azaserine 32 MIC 1 g/ml 15
L-Methionine-S-sulfoximineb 30 MIC 8–12 g/ml
JFD01307SCb 22 MIC 8–16 g/ml
UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-
meso-2,6-diaminopimelyl-D-alanyl-D-alanine
CDD-343074 58 50
Bleomycin 57 MIC 0.1 g/ml CDD database
Hydroxymethylbilane ChemDiv 4286-0015d 45 IC50 3.38 Mc CDD database
Porfimer 45 CDD database
a Examples of biomolecules essential for the metabolism and survival ofM. tuberculosis and their structural analogs are shown as a proof of the principle that molecular mimics
with medicinal properties can be rapidly identified. Some of these molecules have known activities againstM. tuberculosis. CDD stands for Collaborative Drug Discovery, a drug
database and mining software. % similarity was calculated in the CDD database using ChemAxon fingerprints and Tanimoto similarity.
b Molecules identified by 3-D pharmacophore searching.
c IC50, 50% inhibitory concentration.
d MLSMR data set for dose response.
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biosynthetic pathway in M. tuberculosis, JFD01307SC and
L-methionine-S-sulfoximine may target enzymes involved in glu-
tamine biosynthesis.
Essential metabolites of the peptidoglycan, chorismate, and
tetrapyrrole pathways and their mimics. The Tanimoto similar-
ity searchingmethodologywas utilized to search theCollaborative
Drug Discovery TB database formimics of the essential molecules
of the peptidoglycan, chorismate, and tetrapyrrole biosynthetic
pathways. The results for these searches are shown in Tables 1, 2
and 3. Clearly, the mimics exhibit a range of chemical structures
that in many cases do not appear to be obvious structural analogs
of the essential molecules. For example, the glycopeptide antibi-
otic bleomycin has 57% molecular similarity to UDP-N-
acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelyl-
D-alanyl-D-alanine, commonly known as disaccharyl
pentapeptide, and a MIC of 0.1 g/ml (36). This study reported
that guinea pigs treated with bleomycin had smaller lesions and
fewer acid-fast bacilli than untreated guinea pigs and a prolonged
survival time. Future efforts will examine the inhibition of
Rv2153c (MT2212) by bleomycin in addition to its whole-cell
activity against anM. tuberculosis strain overexpressing this gene.
DISCUSSION
A powerful and widely accepted method for developing chemical
probes for and inhibitors of a target protein is to determine the
structure of the protein and identify or design molecules that fit
the active site of the protein. Structure-based optimization of
these starting points by leveraging X-ray crystal structures of the
target essential gene product bound to the essential metabolite or
its close analogs would provide a starting point for developing
more potent molecules (37, 38). However, these enzyme inhibi-
tors may still lack whole-cell activity and in vivo efficacy. This
approach also requires the structure of the protein to be known
and available. We assume that the fundamental knowledge of the
shape of the substrate for an essential enzyme can be used to infer
details of the binding site requirements (39). We herein have pro-
posed a strategy for leveraging the essential molecules ofM. tuber-
culosis to arrive at potent antitubercular small molecules with sig-
nificant promise as chemical probes that may ultimately inspire
preclinical drug candidates. Optimally, this involves choosing
mimics from a database of small-molecule inhibitors ofM. tuber-
culosis growth, such as the CDD TB database.
This is a systematic approach for drug discovery which begins
with identification of targets in the pathogen. As selection of can-
didate inhibitory compounds is based on the identities of verified
targets, the pathways affected and the likely mechanism of action
are known a priori. While we cannot discount the potential for
small-molecule analogs of essential metabolites exhibiting affinity
for other mycobacterial targets, attempts to maintain significant
similarity to the essential metabolite should effectively minimize
this promiscuity. This might also be predicted by understanding
the 2-D or 3-D pharmacophore similarity to other metabolites of
the essential target mimic. This is a significant advantage, since a
drug with a novel mechanism of action is a necessity for killing
those strains of M. tuberculosis that are resistant to one or more
current TB drugs.
The examples of azaserine, JFD01307SC, and L-methionine-S-
sulfoximine provide a proof of principle that mimics of essential
metabolites, as identified through cheminformatic methods, may
represent effective molecules with anti-TB activity in vitro. It
should be noted that gabapentin and nine additional molecules
with significant Tanimoto and/or 3-D-pharmacophore-assessed
similarity to L-glutamate (see Table S4 in the supplemental mate-
rial) did not showactivity againstwild-typeM. tuberculosis and the
gltB-overexpressing strain in our study, illustrating our conclu-
sion that molecular mimicry, as judged by Tanimoto similarity or
fit (technically defined as the FitValue in Discovery Studio) to a
given pharmacophore model for a metabolite, does not singularly
meet the criteria for effective inhibition of the putative enzyme.
Further studies are necessary to probe the relationship between
activity against the intended biological target and the Tanimoto
similarity between the associatedmetabolite and itsmimics as well
as the calculated fit of mimics to the metabolite pharmacophore
model. Clearly, the degree of Tanimoto similarity is dependent on
the molecular fingerprints chosen. We observed a range of pair-
wise Tanimoto similarities (25.6% to 48.8%) for L-glutamate and
azaserine using FCFP_6 or Molecular Design Limited (MDL) fin-
gerprints, respectively. A best practice may involve sampling a
subset of available fingerprint algorithms or using amethodology,
like that from ChemAxon, as done in this study, where similarity
scores consistently neared themidrange. Additionally, it is evident
that pharmacophore models are tunable, given the chemical fea-
tures one chooses to include or ignore. Thus, it is our anticipation
that optimization of pharmacophore search models will be neces-
sary to further leverage our methodology for choosing mimics of
essential metabolites. This is neither unexpected nor completely
dissimilar from what we have learned in high-throughput screen-
ing campaigns, where the choice of compound library and assay
are critical for success.
These data illustrate that a single cheminformatics method is
not universally applicable in predicting the specificity of a syn-
thetic molecule for the target essential enzyme. Approximately
40% of genes ofM. tuberculosis have yet to be functionally anno-
tated (16). Our lack of information on the pathways constituted
by enzymes encoded by these hypothetical genes means that a
large number of metabolites cannot be accounted for at this stage
of study. Identification of all metabolites of M. tuberculosis is a
major hurdle that diminishes the ability of our approach to iden-
tify a molecular mimic with high specificity to the target essential
enzyme. The potential does exist, however, for the implementa-
tion of medicinal chemistry techniques to optimize these initially
chosen molecular mimics for selectivity as well as potency. These
medicinal chemistry operations would be part of a more global
optimization of the chemical structure of the mimic, with regard
to pharmacokinetic, pharmacodynamic, and safety profiles, in or-
der to transition from chemical probe to lead molecule and ulti-
mately to drug candidate. Additionally, cheminformatic tech-
niques may have to be developed and leveraged to choose mimics
for their similarity to a given metabolite and dissimilarity to all
other metabolites.
The time-testedmethod of screening for growth inhibitors has
also been a useful approach in finding TB drugs (for example, the
recent discoveries of R207910 andOPC-67683), but often themo-
lecular target of the inhibitor remains unknown at the end of a
successful screen (40, 41). Indeed, Andries et al. resorted towhole-
genome sequencing of strains susceptible and resistant toR207910
in order to ascertain that its target is likely to be a subunit of M.
tuberculosis ATP synthase encoded by atpE (40). Our approach
obviates the initial requirement for identification of a molecular
target(s) and thereby accelerates the drug discovery process, re-
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ducing the associated costs. It should be noted that it is unlikely
that themolecularmimicrymethod shown here would have iden-
tified R207910, as this compound targets the Fo subunit of ATP
synthase. This subunit in itself is not an enzyme and does not
generate an essential metabolite. Another limitation of our ap-
proach is that a molecule that mimics an essential metabolite and
inhibits the corresponding essential enzyme may not be active
against the whole-cell organism for numerous reasons, including
lack of penetration, active efflux or metabolism, and clearance by
the organism or the host.
Our approach also allows for selective targeting of the patho-
gen. Selection of pathways and targets that are present only in the
pathogen reduces the probability of toxicity to the host. According
to our analysis using the BioCyc pathway/genome database
(PGDB), the three pathways studied in this work, namely, biosyn-
thesis of peptidoglycan, tetrapyrroles, and chorismate, are absent
in the human host. Yet it should be noted that there is a possibility
for cross toxicity to the host itself or for cross toxicity from unin-
tended toxicity to the resident microbiome in the host.Mycobac-
terium bovis, another organism that belongs to the same genus as
M. tuberculosis, also possesses the pathways for biosynthesis of
peptidoglycan, tetrapyrroles, and chorismate. This organism
causes bovine tuberculosis and, thus, is of major concern to the
cattle industry. Using the BioCyc database, we compared the ge-
nomes ofM. bovis and Bos taurus, domestic cattle, and found that
the three pathways are present only in the pathogen. Therefore,
developing drugs to target these pathways is likely to have selective
toxicity to the pathogen when administered to the host to treat
mycobacterial infections.
We have elaborated an intermediate strategy between high-
throughput screening and rational structure-based drug design,
leveraging knowledge of the essential M. tuberculosis genes and
consequently essential pathways and their associated enzymes to
arrive at essential molecules and their analogs. Our definition of
the essential molecules of M. tuberculosis and their partial enu-
meration are clearly reliant on the assumptions made to establish
the essential genes ofM. tuberculosis (6, 15). We assert that a col-
lection of these essential molecules and of others that have yet to
be identified is what ultimately is required for determining the
essential metabolic functions of the organism. A perturbation in
the concentration or availability of these molecules is likely to
adversely affect the organism’s viability. A rational way to alter the
critical concentrations of these essential molecules in vivo is to
utilize a compound that mimics its structural and chemical prop-
erties as a competitive inhibitor of the essential enzyme. An analog
that is able to strongly bind to the active site of the enzyme and
thereby prevent interaction with the native essential molecules is
likely to competitively inhibit the function and eventually lead to
stasis or the death of the organism. A continued evolution of this
set of genes and pathwaysmay be requisite tomore accurately and
comprehensively reveal the essential targets under a given set of
growth conditions deemed to be relevant for a specific disease
state. Of course, a scenario in which an approved drug is found to
be ametabolitemimic could present itself, and through repurpos-
ing, the mimic could represent a novel antitubercular agent with
little if any need for optimization prior to clinical trials.
MATERIALS AND METHODS
Bacterial strains, mutagenesis, and gene essentiality. A
clinical isolate ofM. tuberculosis, CDC1551, was used as the host organism. It
was grown in Middlebrook 7H9 medium (Difco) supplemented with 0.2%
glycerol, 10%(vol/vol) oleic acid-albumin-dextrose-catalase (OADC;Becton
Dickinson), and 0.05% Tween 80 at 37°C. Mutagenesis using the Himar1
transposon, isolation, and genotyping of mutants were undertaken as de-
scribed in our previous work (15). Any gene in which we identified a
transposon insertion disruption was deemed nonessential for in vitro
survival. Once these initial nonessential and essential gene lists were
established, three filter operations were performed to refine both
groups. The first filter, designated here the 5= 80%/3= 100-bp test,
returned nonessential genes with distal insertions within 20% (for
small genes) or 100 bp of the 3= end to the essential list because such
insertions may not significantly affect the product’s function. The sec-
ond filter, called the operon test, reclassified essential genes as nones-
sential if they belonged to an operon that was disrupted in a more
proximal gene. Therefore, such genes were not essential for the in vitro
growth of those mutants. The 4,590-bp gltB open reading frame was
cloned from M. tuberculosis CDC1551 genomic DNA by PCR using
primers MT3974-P1 (5=-GGGGACAAGTTTGTACAAAAAAGCAGG
CTTAAGGAGGTGTGGGTATGACGCCTAAG-3=) and MT3974-P2
(5=-GGGGACCACTTTGTACAAGAAAGCTGGGTATCAGCCATGC
GCAGCCGCCATG-3=). A fully sequenced and mutation-free clone
was recombined into the Escherichia coli-M. tuberculosis Gateway-
compatible knock-in shuttle vector pGS400K (a variant of pGS400H
which features kanamycin selection [42]). M. tuberculosis CDC1551
was transformed with the resulting plasmid, pGS400K-gltB(tb), by
using standard techniques (43), and transformants were obtained after
3 to 4 weeks of growth on 7H10 plates (Becton Dickinson) containing
20 g/ml kanamycin (Sigma). A gltB knock-in strain was grown in
Middlebrook 7H9 broth, total RNA was isolated using standard tech-
niques (44), and the expression of gltB was quantified by real-time
RT-PCR.
Determination of essential metabolic pathways, essential mole-
cules, and analogs. The BioCyc PGDB also included a database of pre-
dicted metabolic pathways in M. tuberculosis, along with the genes in-
volved in each pathway (17). This database was used as a starting point for
determining the essentiality of each pathway. The BioCyc PGDBwas used
to map the putative reactions catalyzed by enzymes that were assessed to
be essential in our analysis. The database collects the molecular structures
and formulas of the reactants and products for each enzyme. This infor-
mation was used to generate a database of putative essential molecules of
M. tuberculosis which comprise the reactants and products of enzymes
that are essential for the growth and survival of the organism.
Determination of MICs.We determined the MICs of all compounds
in this study using the broth dilutionmethod (34). For this, we inoculated
105 wild-typeM. tuberculosis bacilli and bacilli of the gltB knock-in strain
separately in 2.5 ml of 7H9 broth without detergent and added the com-
pounds by 2-fold serial dilutions.We incubated these cultures at 37°C and
evaluated them for granulation, ameasure of growth, by visual inspection
at 7 and 14 days. For those samples with diminished growth compared to
that of a no-drug control, we determined numbers of CFU.
CDD database. Structural analogs or mimics of the putative essential
molecules were then compiled by conducting similarity searches using the
CDD TB database (Collaborative Drug Discovery Inc., Burlingame, CA),
which has been described previously (27), with applications for collabo-
rative research (28). This consists of several TB screening data sets col-
lected and uploaded from SDF files and mapped to custom protocols,
including the data sets of the NIAID (n 3,748), GVK BIO (n 2,880)
(45), TAACF (n  812), and MLSMR (n  220,463) (45), known TB
drugs (n 13) (38), TB candidates of Ballell et al. (n 48) (46), and SAR
data collated from the TB literature (n  6,770) (27). In addition, the
CDDdatabase also includes FDA-approved drugs (n 2,815) and vendor
molecule libraries (27).
3-Dpharmacophore. 3-D computationalmolecularmodeling studies
were carried out using Catalyst in Discovery Studio 2.5.5 (Accelrys, San
Diego, CA). A common-feature (HipHop) pharmacophore model was
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generated around L-glutamate. Such pharmacophores attempt to describe
the arrangement of key features that are important for biological activity
and have been widely described (47, 48). Ten pharmacophores were cre-
ated in Discovery Studio (note that all had slightly different features, etc.).
Pharmacophore 4 consisted of a negative ionizable, a positive ionizable,
and a hydrogen bond acceptor feature (Fig. S2).
The database of FDA-approved drugs (n  2,815) from the CDD
database was downloaded as an SDF file and converted to a 3-D Catalyst
database after generating up to 100 molecule conformations with the
FAST conformer generation method, with a maximum energy threshold
of 20 kcal/mol. In addition, the Maybridge vendor database (n 57,181)
was generated in three dimensions in the same way. The common-feature
pharmacophore model was then applied to screen these databases using
the FAST searchmethod in the samemanner as previously described (49).
The quality of the molecule mapping to the pharmacophore was deter-
mined by the FitValue, which is dependent on the proximity of a com-
pound to the pharmacophore feature centroids and the weights assigned
to each centroid, where a higher FitValue represents a better fit. Com-
pounds were then selected for purchase and testing.
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